Oncopharmpod

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter. A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine). Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Bibliography: 1.. 2019 Systematic Review of Published Cases: https://doi.org/10.1111/dme.14050 2. Mass General Data & Publication: https://jamanetwork.com/journals/jamaoncology/fullarticle/2822927 3. Japanese Claims Data & Pub: https://doi.org/10.1111/jdi.14362 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in patients receiving certain bispecifics -semaglutide-alectinib drug interaction -Safety (n = ~40) of MMR vaccine in patients post-Auto transplant on maintenance daratumumab Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022) Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2 Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

DPYD testing is more complicated than one would think! We talk through the steps to consider when initiating DPYD testing at your site. Resources below: Guide for implementing DPYD testing at your site: https://doi.org/10.1002/cpt.3567 CPIC Dosing Guidline: https://doi.org/10.1002/cpt.911 CPIC DPYD Resources: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/

We are back with lots of OncoPharm updates: 1. The belantamab mafodotin REMS program details are available....and it's a lot. How will belantamab mafodin-regimens be used with the upcoming MAJESTIC-3 data of teclistamab-daratumumab? 2. The capecitabine label is updated and calls for pre-treatment DPYD testing 3. Daratumumab gets an FDA approval for high-risk smoldering myeloma based on the AQUILA study Critique of AQUILA: https://doi.org/10.1093/oncolo/oyaf216 4. A pertuzumab biosimilar (Poherdy) is approved 5. Epcoritamab nets regular approval and a new indication with lenalidomide/rituximab (RR) for Follicular Lymphoma 6. Ziftomenib, a new menin inhibitor, is approved for NPM1 relapsed/refractory AML 7. Sevabertinib, a new HER2 inhibiting TKI, is approved for ERBB2 mutated NSCLC, with evidence of activity in patients previously treated with HER2-antibody-drug conjugates 8. Expected FDA approvals for durvalumab + FLOT in preoperative gastric/GEJ cancer; neoadjuvant pembrolizumb + enforumab vedotin in bl